Edition:
India

Cellectis SA (CLLS.OQ)

CLLS.OQ on NASDAQ Stock Exchange Global Market

25.13USD
11 Dec 2017
Change (% chg)

$0.22 (+0.88%)
Prev Close
$24.91
Open
$25.08
Day's High
$25.45
Day's Low
$24.90
Volume
43,401
Avg. Vol
71,757
52-wk High
$35.07
52-wk Low
$16.33

Latest Key Developments (Source: Significant Developments)

Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - CELLECTIS SA ::CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

Cellectis says cash position at Sept. 30 of $304.1 million
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - CELLECTIS SA ::ANNOUNCED ON MONDAY: CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS AT SEPT 30 STOOD AT $304.1 MLN VS $271.2 MLN AT JUNE 30 .Q3 TOTAL REVENUES AND OTHER INCOME $7.3 MLN VS $12.6 MLN YEAR AGO.Q3 FINANCIAL LOSS $3.4 MLN VS LOSS OF $1.2 MLN YEAR AGO .Q3 NET LOSS ATTRIBUTABLE TO SHAREHOLDERS $26.2 MLN VS LOSS OF $14.1 MLN YEAR AGO.EXPECTS ITS CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATIONS INTO 2020.  Full Article

Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Cellectis SA :FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN.Says ‍working with investigators and clinical sites to obtain IRB'S approval on revised protocols and resume patient enrollment​.Cellectis SA says ‍agreed with FDA to decrease of cohort dose level to 6.25x10(4) UCART123 cells/ in Phase 1 UCART123 protocols​.  Full Article

Cellectis Announces the Issuance of US Patent 9,458,439
Wednesday, 5 Oct 2016 

Cellectis SA : Announced on Tuesday the issuance of U.S. patent 9,458,439 – which claims gene inactivation by use of chimeric restriction endonucleases .This patent granted by the USPTO to the Institut Pasteur and Boston Children's Hospital naming Dr Andre Choulika and Pr. Richard C. Mulligan as co-inventors, is exclusively licensed to Cellectis.  Full Article

Cellectis says first patient treated in phase 1 trial of UCART19
Tuesday, 21 Jun 2016 

Cellectis SA : Cellectis SA says first patient treated in phase 1 trial of ucart19 in pediatric acute B lymphoblastic leukemia . Cellectis announces first patient treated in phase 1 trial of ucart19 in pediatric acute b lymphoblastic leukemia (b-all) .Announces First Patient Treated In Phase 1 Trial Of Ucart19 In Pediatric Acute B Lymphoblastic Leukemia (B-all).  Full Article

Cellectis Q1 net result turns to loss of 6.3 million euros
Thursday, 12 May 2016 

Cellectis : Reported on Wednesday Q1 revenue of 7.0 million euros vs 8.4 million euros last year . Q1 net loss is 29.5 million euros vs profit of 6.3 million euros last year .Expected that its cash, cash equivalents and Current financial assets of 276.5 million euros as of March 31 will be sufficient to fund its current operations through 2018.  Full Article

Cellectis reports first quarter 2016 financial results
Thursday, 12 May 2016 

Cellectis Sa :Cellectis reports first quarter 2016 financial results.  Full Article

Cellectis SA announces RetroNectin supply and license agreement with Takara Bio Inc
Tuesday, 22 Mar 2016 

Cellectis SA:Has entered into a supply and license agreement with Takara Bio Inc for recombinant human fibronectin fragment RetroNectin.Financial terms of the agreement are not disclosed.  Full Article

Cellectis and MabQuest announce immunotherapy partnership
Wednesday, 16 Mar 2016 

Cellectis SA:Announced an immunotherapy partnership with MabQuest on new class of PD-1 antagonist monoclonal antibodies.  Full Article

Cellectis enters into new agreement with CELLforCURE
Tuesday, 19 Jan 2016 

Cellectis SA:Reports that it entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, Cellectis` lead product candidate, with CELLforCURE, an LFB group company.CELLforCURE is to be in charge of implementing cGMP manufacturing processes designed and developed by Cellectis.  Full Article

BRIEF-Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer

* CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)